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Wernicke’s encephalopathy is caused by thiamine deficiency, and is characterized by 
acute mental confusion, ataxia, and ophthalmoplegia. It is also a rare neurologic complica-
tion of hematopoietic stem cell transplantation (HSCT). However, because of its rare in-
cidence, Wernicke’s encephalopathy can easily be overlooked in HSCT patients, and a 
few misleading steps in the early stage of the disease may result in permanent neurologic 
disability or even mortality. We recently encountered a case of Wernicke’s encephalop-
athy in a patient who underwent allogeneic HSCT. Based on our own experience and pre-
viously published documents, we suggest early radiologic surveillance and treatment for 
patients with findings compatible with Wernicke’s encephalopathy following HSCT.
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INTRODUCTION
  Wernicke’s  encephalopathy is named after Dr. Carl 
Wernicke, the Polish neurologist who first described the 
disease in 1881. Initially, the syndrome was characterized 
by a classic triad of acute mental confusion, ataxia, and oph-
thalmoplegia, but this triad was later found to occur in only 
1/3 of the patients [1]. Wernicke’s encephalopathy can be 
clinically diagnosed, when a patient shows central nervous 
system (CNS) symptoms compatible with radiologic evi-
dence, especially on brain magnetic resonance imaging (MRI) 
[2]. This syndrome is well understood to be a consequence 
of thiamine deficiency and most commonly occurs in chronic 
alcoholics who are at risk of an unbalanced diet. However, 
it can occur under any condition that may induce malnu-
trition or malabsorption syndromes leading to thiamine defi-
ciency [3, 4]. 
  Hematopoietic stem cell transplantation (HSCT) does not 
seem to have a strong link with Wernicke’s encephalopathy. 
However, HSCT can commonly cause anorexia, various de-
grees of stomatitis, graft-versus-host disease (GVHD), and 
infections involving the gastrointestinal tract, which lead 
to decreased oral intake and long-term use of total parenteral 
nutrition (TPN). Because commercialized TPN often lack 
thiamine, HSCT recipients are sometimes at risk of develop-
ing thiamine deficiency. However, despite the popular use 
of TPN agents during HSCT, only a few cases of HSCT-asso-
ciated Wernicke’s encephalopathy have been reported world-
wide. We recently observed Wernicke’s encephalopathy in 
a leukemia patient, who underwent allogeneic HSCT, and 
report the case here along with a review of previously re-
ported cases.
CASE REPORT
  A 45-year-old man diagnosed with secondary leukemia 
was admitted to our institute’s hospital for allogeneic HSCT. 
He was first diagnosed with myelodysplastic syndrome (re-
fractory cytopenia with multilineage dysplasia with a 9q 
deletion) 1.5 years ago. At 10 months after the initial diag-
nosis, the patient was readmitted because of dizziness, nausea, 
and abnormal complete blood counts revealing bicytopenia 
(hemoglobin, 7.2 g/dL; white blood cells, 1,200/μL; platelets, 
342,000/μL). Bone marrow examination revealed that the 
erythroid elements were markedly increased up to 71.8% 
of all nucleated cells, with blasts up to  26.9% of non-eryt hroid Korean J Hematol 2010;45:279-81.
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Fig. 1. (A) Increased signal inten-
sities in both medial thalami com-
patible with Wernicke’s encephalo-
pathy clearly seen on a T2-weighted
gradient-recalled echo image. (B)
Relatively decreased signal inten-
sities in both thalami seen on a T2- 
weighted image taken 3 months 
later.
Table 1. Previous reports on HSCT-associated Wernicke’s encephalopathy.
Authors
Year of 
publication
Number of WE 
cases
Type of
HSCT
Means of
diagnosis
Proposed
causes
Thiamine 
prophylaxis
Outcome
Majolini et al. [8] 1990 1 Auto-HSCT Brain MRI Busulfan No Improved
Bleggi-Torres et al. [9] 1997 8 Not specified Autopsy Prolonged TPN Yes All expired
Bleggi-Torres et al. [10] 2000 10 Not specified Autopsy Prolonged TPN Yes All expired
Baek et al. [13] 2005 1 Allo-HSCT Brain MRI Prolonged TPN No Improved
Messina et al. [14] 2007 2 Allo-HSCT Brain MRI Prolonged TPN No Improved
Teive et al. [12] 2008 9 Allo-HSCT Brain MRI, autopsy Prolonged TPN No 8 expired
Kuo et al. [15] 2009 3 Allo-HSCT Brain MRI, autopsy Prolonged TPN No All expired
Abbreviations: HSCT, hematopoietic stem cell transplantation; WE, Wernicke’s encephalopathy; Auto, autologous; TPN, total parenteral
nutrition; Allo, allogeneic. 
cells. Based on the result, acute erythroid leukemia (AML- 
M6) was diagnosed. The patient was quickly treated with 
idarubicin and cytarabine for remission induction. Following 
successful induction treatment, the patient was prepared for 
allogeneic HSCT with his older sister, whose human leuko-
cyte antigen fully matched his, as the donor. 
  Donor cluster of differentiation (CD) 34
+ cells (2.68×10
6/ 
kg) were collected after mobilization of peripheral blood 
stem cells with granulocyte-colony stimulating factor. After 
conditioning the patient with a classic busulfan and cyclo-
phosphamide regimen, the prepared donor cells were infused 
into the patient without any acute complications. During 
the conditioning period, the patient developed grade 4 nausea 
and anorexia and could not receive oral nutrition. TPN was 
quickly applied for providing the much-needed nutritional 
support. The patient gradually recovered from neutropenia 
on day 12 of HSCT without any adverse events, and successful 
engraftment was confirmed by an engraftment assay per-
formed on day 28 of HSCT. However, owing to continued 
loss of appetite and acute GVHD involving the gastro-
intestinal tract, TPN was maintained for over a month.
  On day 48 of HSCT, the patient suddenly developed mental 
confusion, cognitive dysfunction, and asterixis. CNS exami-
nation with brain MR diffusion-weighted imaging revealed 
high signal intensities at the medial thalamus (Fig. 1A). 
Wernicke’s encephalopathy was diagnosed based on the pa-
tient’s history of consistent use of TPN, CNS symptoms, 
and typical radiologic findings, although the thiamine level 
was not checked. At the time of diagnosis, the cyclosporine 
level was 280.1 ng/mL, so calcineurin inhibitor-induced leu-
koencephalopathy was excluded. Thiamine was intrave-
nously administered at a recommended dose of 1.5 g/day, 
resulting in rapid improvement of the CNS symptoms within 
24 h of treatment initiation. The IV thiamine dose was main-
tained for 2 weeks and gradually reduced to peroral admins-
tered maintenance dose of 40 mg/day. Meanwhile, the patient 
recovered completely without any neurologic sequelae, and 
a follow-up brain MRI scan taken 2 weeks after the onset 
of Wernicke’s encephalopathy showed reduced signal in-
tensities in the thalamic areas (Fig. 1B). After a few more 
weeks of observation, the patient was discharged, and up 
to his most recent visit, he has shown no sign of recurrence.Korean J Hematol 2010;45:279-81.
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DISCUSSION
  Thiamine (vitamin B1) plays a vital role in generation 
of energy needed for cerebral activities. It acts as a cofactor 
for enzymes like pyruvate dehydrogenase and α-ketogluta-
rate, which are essential in the Krebs cycle. Thus, thiamine 
deficiency leads to decreased activity of thiamine-dependent 
enzymes, which consequently leads to ineffective cerebral 
energy utilization and neuronal damage [5]. In these con-
ditions, the classic symptoms of Wernicke’s encephalopathy, 
such as ataxia, oculomotor dysfunction, confusion, and vari-
ous degrees of cognitive dysfunction, may appear [4, 6]. 
Although almost all Wernicke’s encephalopathy patients 
show some degree of improvement after initiation of thi-
amine replacement, only about 20% recover completely [4, 
7]. Furthermore, mortality increases dramatically when 
treatment is delayed. It is not surprising that early reports 
show a high mortality rate, considering that the means for 
an early diagnosis were previously rare (Table 1).
  Considering the frequency and amount of TPN needed 
during HSCT, it is not difficult to find the link between 
Wernicke’s encephalopathy and HSCT. However, the occur-
rence of Wernicke’s encephalopathy after HSCT is still a 
rare event, and only a few cases have been reported world-
wide. Almost all published reports, except 1, concluded that 
prolonged TPN was the primary risk factor for HSCT-asso-
ciated Wernicke’s encephalopathy. The only other suggested 
cause was the use of busulfan in the conditioning regimen 
[8]. However, it is not yet clear whether other risk factors 
play a role in triggering such complications, the duration 
of TPN required for the disease to manifest itself is unknown.
  Many authors have recommended the use of a thiamine 
supplement for the prophylaxis against Wernicke’s encepha-
lopathy. However, an earlier publication from a Brazilian 
group reported 8 patients who expired after developing 
Wernicke’s encephalopathy despite using prophylactic thi-
amine (50 mg/day) [9]. Further studies are required to decide 
on an effective prophylactic dose of thiamine and to de-
termine whether thiamine prophylaxis is effective in the 
prevention of Wernicke’s encephalopathy in HSCT patients.
 Initial CNS evaluation and management of the rarely occur-
ring Wernicke’s encephalopathy is not routinely recom-
mended [7, 9-12]. However, we should remember that HSCT 
patients are always at risk of thiamine deficiency. Therefore, 
if an HSCT patient shows compatible signs and symptoms, 
then an early radiologic evaluation should be performed, 
and Wernicke’s encephalopathy should be considered. 
Timely diagnosis and initiation of treatment are mandatory 
in order to minimize CNS complications and unwanted 
mortality.
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